C-terminal variants in CDC42 drive type I interferon-dependent autoinflammation in NOCARH syndrome reversible by ruxolitinib
Friedrich Kapp, Stefanie Kretschmer, Cora Beckmann, Lena Wäsch, Anne Molitor, Raphaël Carapito, Mario Schubert, Nadja Lucas, Solène Conrad, Sylvaine Poignant, Bertrand Isidor, Meino Rohlfs, Ayşenur Paç Kısaarslan, Denny Schanze, Martin Zenker, Annette Schmitt‐Graeff, Brigitte Strahm, Anke Peters, Ayami Yoshimi, Wolfgang Driever, Thomas Zillinger, Claudia Günther, Shovamayee Maharana, Kaomei Guan, Christoph Klein, Stephan Ehl, Charlotte M. Niemeyer, Ekrem Ünal, Seiamak Bahram, Fabian Hauck, Min Ae Lee‐Kirsch, Carsten Speckmann
Topics & Concepts
RuxolitinibPyrin domainInflammasomeImmunologyInnate immune systemMedicineAIM2Cancer researchInflammationMyelofibrosisImmune systemBone marrowInflammasome and immune disordersAutoimmune and Inflammatory Disorders ResearchCytomegalovirus and herpesvirus research